Midazolam Microdosing and Population Pharmacokinetic Modelling to Assess CYP3A Drug-Drug Interactions in Early Clinical Development
- Alternative title
-
Midazolam-Mikrodosierung und populationspharmakokinetische Modellierung zur Bewertung von CYP3A-Arzneimittelinteraktionen in der frühen klinischen Entwicklung
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Heidelberg, Universität Heidelberg, Dissertation, 2021
- Keyword
-
Midazolam
Population
Drug interactions
Arzneimittelwechselwirkung
Metabolismus
Pharmakokinetik
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (who)
-
Universitätsbibliothek Heidelberg
- (when)
-
2021
- Creator
- Contributor
- DOI
-
10.11588/heidok.00029312
- URN
-
urn:nbn:de:bsz:16-heidok-293120
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:46 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wiebe, Sabrina
- Mikus, Gerd
- Universitätsbibliothek Heidelberg
Time of origin
- 2021
Other Objects (12)
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Advanced population pharmacokinetic modelling to quantify selected characteristics of drugs
Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Pharmacokinetic challenges in drug discovery : with 18 tables
Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions : Application of Physiologically-Based Pharmacokinetic Modeling
Individualization of drug therapy considering pharmacokinetic and clinical factors
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Nanodose study of the CYP3A paradigm substrate midazolam to evaluate pharmacokinetic linearity of parent drug before and during CYP3A inhibition
Population pharmacokinetic/-dynamic modeling and model-based simulations to facilitate the appropriate use of antibacterial drugs
Two different approaches for pharmacokinetic modeling of exhaled drug concentrations
Drug discovery and evaluation: safety and pharmacokinetic assays, Vol. 2.
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Advanced population pharmacokinetic modelling to quantify selected characteristics of drugs
Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Pharmacokinetic challenges in drug discovery : with 18 tables
Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions : Application of Physiologically-Based Pharmacokinetic Modeling
Individualization of drug therapy considering pharmacokinetic and clinical factors
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Nanodose study of the CYP3A paradigm substrate midazolam to evaluate pharmacokinetic linearity of parent drug before and during CYP3A inhibition
Population pharmacokinetic/-dynamic modeling and model-based simulations to facilitate the appropriate use of antibacterial drugs
Two different approaches for pharmacokinetic modeling of exhaled drug concentrations
Drug discovery and evaluation: safety and pharmacokinetic assays, Vol. 2.
Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs
Advanced population pharmacokinetic modelling to quantify selected characteristics of drugs
Modern pharmacokinetic-pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Pharmacokinetic challenges in drug discovery : with 18 tables
Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions : Application of Physiologically-Based Pharmacokinetic Modeling
Individualization of drug therapy considering pharmacokinetic and clinical factors
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Nanodose study of the CYP3A paradigm substrate midazolam to evaluate pharmacokinetic linearity of parent drug before and during CYP3A inhibition
Population pharmacokinetic/-dynamic modeling and model-based simulations to facilitate the appropriate use of antibacterial drugs
Two different approaches for pharmacokinetic modeling of exhaled drug concentrations